NEW YORK (GenomeWeb) – Danish miRNA biomarker firm Exiqon today reported its first quarter revenues were up 2 percent year over year.

The company reported DKK32.5 million ($6.0 million) in revenues for the three months ended March 31, compared to DKK31.8 million in the year-ago quarter. It attributed the gain to continued organic growth in its Life Sciences product sales, which rose 5 percent year over year, driven by new products. Exiqon's Services business was down 19 percent year over year during the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.